Near-infrared light-activated IR780-loaded liposomes for anti-tumor angiogenesis and Photothermal therapy

Yang, Xue; Li, Huipeng; Qian, Chenggen; Guo, Yuxin; Li, Chenzi; Gao, Fang; Yang, Ying; Wang, Kaikai; Oupický, David; Sun, Minjie

doi:10.1016/j.nano.2018.06.011

Cited by 54 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 36,37 ] Therefore, anti‐angiogenic therapy using nanotechnology and combining other therapeutic modalities (such as chemotherapy, radiotherapy, phototherapy, and immunotherapy) may achieve synergistic effects and improve antitumor activity significantly. [ 28,29,38–43 ]…”

Section: Introductionmentioning

confidence: 99%

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

Liang

Ballou

et al. 2021

Advanced Materials

View full text Add to dashboard Cite

Anti‐angiogenic therapy, targeting vascular endothelial cells (ECs) to prevent tumor growth, has been attracting increasing attention in recent years, beginning with bevacizumab (Avastin) through its Phase II/III clinical trials on solid tumors. However, these trials showed only modest clinical efficiency; moreover, anti‐angiogenic therapy may induce acquired resistance to the drugs employed. Combining advanced drug delivery techniques (e.g., nanotechnology) or other therapeutic strategies (e.g., chemotherapy, radiotherapy, phototherapy, and immunotherapy) with anti‐angiogenic therapy results in significantly synergistic effects and has opened a new horizon in fighting cancer. Herein, clinical difficulties in using traditional anti‐angiogenic therapy are discussed. Then, several promising applications of anti‐angiogenic nanoagents in monotherapies and combination therapies are highlighted. Finally, the challenges and perspectives of anti‐angiogenic cancer therapy are summarized. A useful introduction to anti‐angiogenic strategies, which may significantly improve therapeutic outcomes, is thus provided.

show abstract

Section: Introductionmentioning

confidence: 99%

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

Liang

Ballou

et al. 2021

Advanced Materials

View full text Add to dashboard Cite

show abstract

“…Nanoformulations incorporating IR780 and other therapeutic agents can also be prepared for cancer combinatorial phototherapy (Table ) . In this regard, Yang et al prepared PEGylated micelles incorporating IR780 and doxorubicin (DOX) for application in cancer chemo‐PTT .…”

Section: Nanomaterials Incorporating Heptamethine Cyanines For Cancermentioning

confidence: 99%

Prototypic Heptamethine Cyanine Incorporating Nanomaterials for Cancer Phototheragnostic

Leitão

Melo‐Diogo

Alves

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Developing technologies that allow the simultaneous diagnosis and treatment of cancer (theragnostic) has been the quest of numerous interdisciplinary research teams. In this context, nanomaterials incorporating prototypic near infrared (NIR)‐light responsive heptamethine cyanines have been showing very promising results for cancer theragnostic. The precisely engineered features of these nanomaterials endow them with the ability to achieve a high tumor accumulation, enabling a tumor's visualization by NIR fluorescence and photoacoustic imaging modalities. Upon interaction with NIR light, the tumor‐homed heptamethine cyanine‐incorporating nanomaterials can also produce a photothermal/photodynamic effect with a high spatio‐temporal resolution and minimal side effects, leading to an improved therapeutic outcome. This progress report analyses the application of nanomaterials incorporating prototypic NIR‐light responsive heptamethine cyanines (IR775, IR780, IR783, IR797, IR806, IR808, IR820, IR825, IRDye 800CW, and Cypate) for cancer photothermal therapy, photodynamic therapy, and imaging. Overall, the continuous development of nanomaterials incorporating the prototypic NIR absorbing heptamethine cyanines will cement their phototheragnostic capabilities.

show abstract

“…Most strategies for PTT depend on constructing nanosystems by means of enhanced permeability and retention effects and conjugation with cell‐specific target ligands. [ 11–15 ] However, growing experimental data indicate that even in relatively ideal situations, the targeting ability of the injected reagent to reach the lesion site is relatively low, [ 16,17 ] such as 1–10 parts per 100 000 for antibody conjugates and ≈0.7% for nanoparticles. [ 16,18–21 ] Compared to nanomaterials, organic photosensitizers with long‐wavelength absorption exhibit good synthetic flexibility and biocompatibility.…”

Section: Introductionmentioning

confidence: 99%

A Single Molecule Drug Targeting Photosensitizer for Enhanced Breast Cancer Photothermal Therapy

Zou

Xiong

et al. 2020

Small

View full text Add to dashboard Cite

Targeting is one of the most important strategies for enhancing the efficacy of cancer photothermal therapy (PTT) and reducing damage to surrounding normal tissues. Compared with the traditional targeting approaches, the active targeting of breast cancer cells in PTT using chemotherapeutic drugs, such as tamoxifen (TAM), in combination with single‐molecule photothermal photosensitizers has superior selectivity and therapeutic effects. However, single‐molecule drug‐targeting photosensitizers for improved PTT efficacy are not widely reported. Accordingly, herein, a near‐infrared induced small‐molecule photothermal photosensitizer (CyT) is developed that actively targets the estrogen receptors (ERs) of breast cancer cells as well as targets mitochondria by structure‐inherent targeting. Cell uptake and cytotoxicity studies using different types of cells show that CyT enhances the efficiency of TAM‐based PTT by targeting ER‐overexpressing breast cancer cells and selectively killing them. In vivo experiments demonstrate that CyT can be used as a photothermal agent for fluorescence imaging‐guided PTT. More importantly, the intravenous injection of CyT results in better targeting and efficiency of tumor inhibition compared with that achieved with the TAM‐free control molecule Cy. Thus, the study presents an excellent small‐molecule photothermal agent for breast cancer therapy with potential clinical application prospects.

show abstract

Near-infrared light-activated IR780-loaded liposomes for anti-tumor angiogenesis and Photothermal therapy

Cited by 54 publications

References 45 publications

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

Monotherapy and Combination Therapy Using Anti‐Angiogenic Nanoagents to Fight Cancer

Prototypic Heptamethine Cyanine Incorporating Nanomaterials for Cancer Phototheragnostic

A Single Molecule Drug Targeting Photosensitizer for Enhanced Breast Cancer Photothermal Therapy

Contact Info

Product

Resources

About